tirzepatide in breast milk Early evidence by InfantRisk Center suggests doesn't meaningfully enter milk, the small study that still under review, found that tirzepatide was either undetectable or barely detectable breast at Tirzepatide and Breastfeeding: Safety Guide

That type of litigation is risky because if a judge were to rule against the drugmakers, it could risk their patent and the billions they make selling those drugs

Endocr Rev 2020;41:bnaa004.PubMedPMC 5

Furthermore, to provide clinicians with an up-to-date and clinically useful resource to support their daily practice, we discuss practical strategies for the prevention and management of GI adverse events

Nakajima, 1989

Future investigations should rigorously assess their long-term safety and economic viability across diverse populations while expanding therapeutic indications, thereby maximizing the clinical benefits for millions of patients globally